

Seung-Jun Oh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4200441/publications.pdf>

Version: 2024-02-01

90
papers

1,368
citations

331670

21
h-index

377865

34
g-index

99
all docs

99
docs citations

99
times ranked

2132
citing authors

#	ARTICLE	IF	CITATIONS
1	PET Imaging of System x _C ^â in Immune Cells for Assessment of Disease Activity in Mice and Patients with Inflammatory Bowel Disease. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1586-1591.	5.0	5
2	Effects of taurine and ginseng extracts on energy metabolism during exercise and their anti-fatigue properties in mice. <i>Nutrition Research and Practice</i> , 2022, 16, 33.	1.9	4
3	¹⁸ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β 2-Amyloid-Negative Amnesic Mild Cognitive Impairment. <i>Yonsei Medical Journal</i> , 2022, 63, 259.	2.2	5
4	Unified Deep Learning-Based Mouse Brain MR Segmentation: Template-Based Individual Brain Positron Emission Tomography Volumes-of-Interest Generation Without Spatial Normalization in Mouse Alzheimer Model. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 807903.	3.4	6
5	Feasibility of ¹⁸ F-Fluorocholine PET for Evaluating Skeletal Muscle Atrophy in a Starved Rat Model. <i>Diagnostics</i> , 2022, 12, 1274.	2.6	3
6	[¹⁸ F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET		

#	ARTICLE	IF	CITATIONS
19	Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy. <i>Nanomaterials</i> , 2020, 10, 91.	4.1	29
20	HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118835.	4.1	7
21	Optimization of the Synthesis of ^{18}F -Deprenyl With Mild ^{18}F -Fluorination and Minimum Precursor Input for PET Imaging of Neuroinflammation. <i>Bulletin of the Korean Chemical Society</i> , 2020, 41, 805-811.	1.9	0
22	Comparative Study in Different Filters for Efficient Sterile Filtration. <i>Bulletin of the Korean Chemical Society</i> , 2020, 41, 824-828.	1.9	2
23	Camphene Attenuates Skeletal Muscle Atrophy by Regulating Oxidative Stress and Lipid Metabolism in Rats. <i>Nutrients</i> , 2020, 12, 3731.	4.1	16
24	Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study. <i>Bioorganic Chemistry</i> , 2020, 99, 103834.	4.1	7
25	Tumour-to-liver ratio determined by ^{68}Ga -DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. <i>EJNMMI Research</i> , 2020, 10, 63.	2.5	22
26	YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation. <i>Oncology Letters</i> , 2020, 20, 72.	1.8	3
27	Glycoprotein IIb/IIIa Receptor Imaging with ^{18}F -GP1 PET for Acute Venous Thromboembolism: An Open-Label, Nonrandomized, Phase 1 Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 244-249.	5.0	27
28	Differences in gray and white matter ^{18}F -THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 357-366.	6.4	19
29	A phase 1, first-in-human study of ^{18}F -GP1 positron emission tomography for imaging acute arterial thrombosis. <i>EJNMMI Research</i> , 2019, 9, 3.	2.5	31
30	Radiation dosimetry of ^{18}F -GP1 for imaging activated glycoprotein IIb/IIIa receptors with positron emission tomography in patients with acute thromboembolism. <i>Nuclear Medicine and Biology</i> , 2019, 72-73, 45-48.	0.6	6
31	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. <i>BMC Neurology</i> , 2019, 19, 211.	1.8	8
32	$^{3\text{-}^2}\text{-Deoxy-}^3\text{-}^{\text{TM}}\text{-}^{18}\text{F}$ -Fluorothymidine and ^{18}F -Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1713-1722.	6.4	8
33	Diagnostic accuracy and safety of $^{16}\beta\text{-}^{18}\text{F}$ -fluoro- $^{17}\beta\text{-}^2$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 546-555.	10.7	85
34	Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity. <i>PLoS ONE</i> , 2019, 14, e0226265.	2.5	6
35	Comparison of Amyloid β^2 and Tau Spread Models in Alzheimer's Disease. <i>Cerebral Cortex</i> , 2019, 29, 4291-4302.	2.9	19
36	Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging. <i>NeuroImage</i> , 2019, 186, 690-702.	4.2	58

#	ARTICLE	IF	CITATIONS
37	Glutathione-responsive PEGylated GQD-based nanomaterials for diagnosis and treatment of breast cancer. <i>Journal of Industrial and Engineering Chemistry</i> , 2019, 71, 301-307.	5.8	18
38	Head to head comparison of [¹⁸ F] AV-1451 and [¹⁸ F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 432-442.	6.4	51
39	P2-359: RELATION NETWORKS OF NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECTRUM: TAU, AMYLOID, AND CORTICAL ATROPHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P827.	0.8	0
40	P1-396: COGNITION AND NEUROFIBRILLARY DEGENERATION IN PATIENTS WITH AMYLOID-NEGATIVE MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P454.	0.8	0
41	P3-089: DATA-DRIVEN PATHOLOGICAL POSITIVITY OF ALZHEIMER DISEASE: AN EXPLORATORY STUDY OF DYNAMIC BIOMARKER CAUSALITY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1099.	0.8	0
42	P3-433: NEURAL SUBSTRATES OF COGNITIVE RESERVE IN THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P1277.	0.8	0
43	Optimized statistical parametric mapping for partial-volume-corrected amyloid positron emission tomography in patients with Alzheimer's disease and Lewy body dementia. <i>Journal of the Korean Physical Society</i> , 2017, 70, 454-459.	0.7	0
44	[¹⁸ F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer. <i>Cancer Research</i> , 2017, 77, 7120-7130.	0.9	5
45	[P1-129]: PREDICTION MODEL OF TAU PROPAGATION IN AD SPECTRUM USING FUNCTIONAL NETWORK. <i>Alzheimer's and Dementia</i> , 2017, 13, P291.	0.8	0
46	Full automatic synthesis of [¹⁸ F]THK-5351 for tau protein PET imaging in Alzheimer's disease patients: 1 year experience. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 314, 1587-1593.	1.5	1
47	[P4-212]: HEAD-TO-HEAD COMPARISON OF [¹⁸ F] AV-1451 AND [¹⁸ F] THK5351 FOR TAU IMAGING IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1347.	0.8	1
48	Longitudinal Decline of Striatal Subregional [¹⁸ F]FP-CIT Uptake in Parkinson's Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 304-313.	1.0	12
49	A Randomized Feasibility Study of [¹⁸ F]-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
50	[P2-361]: SURFACE-BASED ANALYSIS OF SUBCORTICAL STRUCTURES IN TAU AND AMYLOID PET IMAGING: AN ALZHEIMER'S DISEASE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P762.	0.8	0
51	[P2-406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING [¹⁸ F]-THK5351 PET IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P786.	0.8	0
52	[P2-424]: PROTECTIVE EFFECTS OF EDUCATION ON THK-5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON-ALZHEIMER PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P798.	0.8	0
53	[P3-319]: MILD COGNITIVE IMPAIRMENT CLASSIFICATION USING DEEP LEARNING. <i>Alzheimer's and Dementia</i> , 2017, 13, P1070.	0.8	0
54	[P3-337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1082.	0.8	0

#	ARTICLE	IF	CITATIONS
55	[P4â€“046]: PARTIAL VOLUME SUSCEPTIBILITY OF TAU PET: REGIONWISE ASSESSMENT AND COMPARISON WITH AMYLOID PET. <i>Alzheimer's and Dementia</i> , 2017, 13, P1274.	0.8	0
56	[P4â€“253]: QUANTITATIVE ANALYSIS AND CORRELATION WITH COGNITIVE FUNCTION OF Fâ€“18 THKâ€“5351 PET IN SUBJECTIVE MEMORY IMPAIRMENT, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1377.	0.8	0
57	[P1â€“454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€“5351 UPTAKES IN PATIENTS WITH ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P460.	0.8	0
58	[O1â€“08â€“01]: PATTERNS OF REGIONAL TAU ACCUMULATION INDICATIVE OF THREE DIFFERENT TYPES OF ALZHEIMER'S DISEASE (AD): THK5351â€“PETâ€“BASED REPLICATION OF PATHOLOGYâ€“BASED AD CLASSIFICATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P206.	0.8	0
59	Striatofrontal Deafferentiation in MSA-P: Evaluation with [18F]FDG Brain PET. <i>PLoS ONE</i> , 2017, 12, e0169928.	2.5	13
60	Different loss of dopamine transporter according to subtype of multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 517-525.	6.4	34
61	Subregional Pattern of Striatal Dopamine Transporter Loss on ¹⁸ F FP-CIT Positron Emission Tomography in Patients With Pure Akinesia With Gait Freezing. <i>JAMA Neurology</i> , 2016, 73, 1477.	9.0	24
62	Biological evaluation of new [¹⁸ F]Fâ€“labeled synthetic amino acid derivatives as oncologic radiotracers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 404-410.	1.0	4
63	Synthesis and evaluation of 6-(3-[18F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiofenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging A β 2 plaques. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2043-2052.	3.0	15
64	Exploratory Clinical Investigation of (4 <i>S</i>)-4-(3- ¹⁸ F-Fluoropropyl)-l-Glutamate PET of Inflammatory and Infectious Lesions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 67-69.	5.0	24
65	Simple preparation of new [18F]F-labeled synthetic amino acid derivatives with two click reactions in one-pot and SPE purification. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 317-326.	1.0	6
66	¹⁸ Fâ€“fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke. <i>Journal of Neuroimaging</i> , 2015, 25, 652-655.	2.0	8
67	Hippocampal volume and shape in pure subcortical vascular dementia. <i>Neurobiology of Aging</i> , 2015, 36, 485-491.	3.1	37
68	P2-208: INCIDENT CEREBRAL MICROBLEEDS IN SUBJECTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: LONGITUDINAL STUDY. , 2014, 10, P548-P549.		0
69	IC-P-017: BLINDED VISUAL EVALUATION AND QUANTITATIVE SUVR THRESHOLD CLASSIFICATION OF [18F]FLUTEMETAMOL PET IMAGES IN JAPANESE SUBJECTS. , 2014, 10, P15-P15.		1
70	P3-217: BLINDED VISUAL EVALUATION AND QUANTITATIVE SUVR THRESHOLD CLASSIFICATION OF [18F]FLUTEMETAMOL PET IMAGES IN JAPANESE SUBJECTS. , 2014, 10, P710-P710.		0
71	An Unusual Case of Anaphylaxis After Fluorine-18-Labeled Fluorodeoxyglucose Injection. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 201-204.	1.0	7
72	Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 44-51.	1.0	57

#	ARTICLE	IF	CITATIONS
73	Development of a new precursor-minimizing base control method and its application for the automated synthesis and SPE purification of [¹⁸ F]fluoromisonidazole ([¹⁸ F]FMISO). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 731-735.	1.0	17
74	Effect of Animal Condition and Fluvoxamine on the Result of [¹⁸ F]N-3-Fluoropropyl-2 ¹² -carbomethoxy-3 ¹² -(4-iodophenyl) Nortropane ([¹⁸ F]FP-CIT) PET Study in Mice. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 27-33.	1.0	8
75	The Feasibility of ¹⁸ F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 57-64.	1.0	13
76	Comparison of two full automatic synthesis methods of 9-(4-[¹⁸ F]fluoro-3-hydroxymethylbutyl)guanine using different chemistry modules. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1758-1763.	1.5	5
77	Tumoral accumulation of long-circulating, self-assembled nanoparticles and its visualization by gamma scintigraphy. <i>Macromolecular Research</i> , 2008, 16, 15-20.	2.4	13
78	Comparison of synthesis yields of 3 ² -deoxy-3 ² -[¹⁸ F]fluorothymidine by nucleophilic fluorination in various alcohol solvents. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 80-82.	1.0	21
79	The automatic production of ¹⁶ β-[¹⁸ F]fluoroestradiol using a conventional [¹⁸ F]FDG module with a disposable cassette system. <i>Applied Radiation and Isotopes</i> , 2007, 65, 676-681.	1.5	32
80	Simple and highly efficient synthesis of 3 ² -deoxy-3 ² -[¹⁸ F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1406-1409.	6.4	46
81	^{99m} Tc-labeled 1-thio-β-d-glucose as a new tumor-seeking agent: Synthesis and tumor cell uptake assay. <i>Applied Radiation and Isotopes</i> , 2006, 64, 207-215.	1.5	30
82	Simple and high radiochemical yield synthesis of 2 ² -Deoxy-2 ² -[¹⁸ F]fluorouridine via a new nosylate precursor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1237-1246.	1.0	4
83	Fully automated synthesis of [¹⁸ F]fluoromisonidazole using a conventional [¹⁸ F]FDG module. <i>Nuclear Medicine and Biology</i> , 2005, 32, 899-905.	0.6	81
84	Late Intravascular Ultrasound Findings of Patients Treated with Brachytherapy for Diffuse In-Stent Restenosis. <i>Sunhwan'gi</i> , 2004, 34, 856.	0.3	0
85	Fully automated synthesis system of 3 ² -deoxy-3 ² -[¹⁸ F]fluorothymidine. <i>Nuclear Medicine and Biology</i> , 2004, 31, 803-809.	0.6	78
86	Long-Term Outcomes after Treatment of Diffuse In-Stent Restenosis with Rotational Atherectomy Followed by Beta-Radiation Therapy with a ¹⁸⁸ Re-MAG3-Filled Balloon. <i>Sunhwan'gi</i> , 2004, 34, 930.	0.3	1
87	Automated preparation of ¹⁸⁸ Re-labeled radiopharmaceuticals for endovascular radiation therapy. <i>Applied Radiation and Isotopes</i> , 2003, 59, 225-230.	1.5	17
88	High radiochemical yield synthesis of 3 ² -deoxy-3 ² -[¹⁸ F]fluorothymidine using (5 ² -O-dimethoxytrityl-2 ² -deoxy-3 ² -O-nosyl-β-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. <i>Nuclear Medicine and Biology</i> , 2003, 30, 151-157.	0.6	75
89	Synthesis of ^{99m} Tc-ciprofloxacin by different methods and its biodistribution. <i>Applied Radiation and Isotopes</i> , 2002, 57, 193-200.	1.5	58
90	Intravascular ultrasound analysis of beta radiation therapy for diffuse in-stent restenosis to inhibit intimal hyperplasia. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 169-173.	1.7	10